Second-Line Combo Fails to Improve Survival in SCLC

(MedPage Today) -- A combination treatment for relapsed small cell lung cancer (SCLC) involving a recently approved drug failed to improve overall survival (OS) versus standard chemotherapy, though it was certainly less toxic, a phase III trial...